Endoscopic Fluorescence Detection of Intraepithelial Neoplasia in Barrett's Esophagus after Oral Administration of Aminolevulinic Acid

T. Stepinac; C. Felley; P. Jornod; N. Lange; T. Gabrecht; C. Fontolliet; P. Grosjean; G. van Melle; H. van den Bergh; P. Monnier; G. Wagnières; G. Dorta

doi:10.1055/s-2003-41514

Endoscopy 2003; 35(8): 663-668
DOI: 10.1055/s-2003-41514

Original Article

Endoscopic Fluorescence Detection of Intraepithelial Neoplasia in Barrett's Esophagus after Oral Administration of Aminolevulinic Acid

T. Stepinac ¹ , C. Felley ² , P. Jornod ² , N. Lange ¹ , T. Gabrecht ¹ , C. Fontolliet ³ , P. Grosjean ⁴ , G. van Melle ⁵ , H. van den Bergh ¹ , P. Monnier ⁴ , G. Wagnières ¹ , G. Dorta ²

¹ Institute of Environmental Engineering, Swiss Federal Institute of Technology, Lausanne, Switzerland
² Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois Hospital, Lausanne, Switzerland
³ Institute of Pathology, Centre Hospitalier Universitaire Vaudois Hospital, Lausanne, Switzerland
⁴ Department of ENT, Centre Hospitalier Universitaire Vaudois Hospital, Lausanne, Switzerland
⁵ Division of Statistics, Lausanne University, Lausanne, Switzerland

Abstract

Background and Study Aims: Barrett's esophagus is strongly associated with adenocarcinoma. Early malignant transformation of the Barrett's mucosa is often not visible endoscopically and may remain undetected until the invasive adenocarcinoma stage. Endoscopic surveillance is currently carried out on random four-quadrant biopsies at 1-2 cm intervals. Endoscopic fluorescence detection of protoporphyrin IX induced by 5-aminolevulinic acid can identify premalignant lesions. This study evaluates endoscopic fluorescence detection in patients having Barrett's esophagus and compares the results to those of standard endoscopy with random four-quadrant biopsies.Patients and Methods: The study included 30 examinations in 28 patients (22 men, 6 women; age range 37-78 years, mean age 60 years,), with five patients having known intraepithelial neoplasia. A dose of 20 mg/kg of 5-aminolevulinic acid was given orally 5 hours before examination. Random four-quadrant biopsies were performed 4-6 weeks before endoscopic fluorescence detection.Results: Of the biopsies taken during the endoscopic fluorescence detection procedure, 28 % (23/81) were true positives. More than one-third of the false-positive results were due to inflammation. None of the 97 control biopsies taken on nonfluorescing areas during endoscopic fluorescence detection were dysplastic. Endoscopic fluorescence detection showed low-grade intraepithelial neoplasia in five patients which was not diagnosed with random four-quadrant biopsies, while random four-quadrant biopsies alone showed three low-grade intraepithelial neoplasias that were invisible during endoscopic fluorescence detection. All high-grade intraepithelial neoplasias or adenocarcinomas (2/2) were detected with both methods.Conclusions: Fluorescence detection achieved a similar performance when compared with four-quadrant random biopsy, but resulted in fewer biopsies (81 for endoscopic fluorescence detection vs 531 for random four-quadrant biopsies).

Full Text

References

1 Spechler S J. Barrett's esophagus. N Engl J Med. 2002; 346 836-842
2 Spechler S J. Epidemiology and natural history of gastroesophageal reflux disease. Digestion. 1992; 51 24-29
3 Winters C, Spurling T, Chobanian S. et al . Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987; 92 118-124
4 Drewitz D, Sampliner R, Garewal H. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997; 92 212-215
5 O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol. 1999; 94 2037-2042
6 Overholt B. Results of photodynamic therapy in Barrett's esophagus: a review. Can J Gastroenterol. 1999; 13 393-396
7 Levine D S. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin N Am. 1997; 26 613-634
8 Falk G W. Barrett's esophagus. Gastroenterology. 2002; 122 1569-1591
9 Heitmiller R F, Redmond M, Hamilton S R. Barrett's esophagus with high-grade dysplasia - an indication for prophylactic esophagectomy. Ann Surg. 1996; 224 66-71
10 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 1998; 93 1028-1032
11 Tytgat G NJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett's esophagus) have any real value?. Endoscopy. 1995; 27 19-26
12 Falk G W, Chittajallu R, Goldblum J R. et al . Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology. 1997; 112 1787-1797
13 Waxman I. Endosonography in columnar-lined esophagus. Gastroenterol Clin N Am. 1997; 26 607-612
14 Levine M S, Herman J B, Furth E E. Barrett's esophagus and esophageal adenocarcinoma - the scope of the problem. Abdom Imaging. 1995; 20 291-298
15 Canto M IF, Setrakian S, Willis J E. et al . Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: An in vivo and ex vivo study. Endoscopy. 2001; 33 391-400
16 Peng Q, Berg K, Moan J. et al . 5-aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997; 65 235-251
17 Stepp H, Sroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience. Endoscopy. 1998; 30 379-386
18 Gossner L, Stolte M, Sroka R. et al . Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998; 114 448-455
19 Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res. 1997; 68 31-37
20 Pech O, Gossner L, May A. et al . Management of Barrett's oesophagus, dysplasia and early adenocarcinoma. Best Pract Res Clin Gastroenterol. 2001; 15 267-84
21 Endlicher E, Knuechel R, Hauser T. et al . Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-aminolaevulinic acid sensitisation. Gut. 2001; 48 314-349
22 Brand S, Wang T D, Schomacker K T. et al . Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Gastrointest Endosc. 2002; 56 479-487
23 Messmann H, Endlicher E, Gelbmann C M. et al . Fluorescence endoscopy and photodynamic therapy. Dig Liver Dis. 2002; 34 754-761
24 Mayinger B, Neidhardt S, Reh H. et al . Fluorescence induced with 5-aminolevulinic acid for the endoscopic detection and follow-up of esophageal lesions. Gastrointest Endosc. 2001; 54 572-578
25 Kelty C J, Brown N J, Reed M WR. et al . The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci. 2002; 1 158-168
26 Sackmann M. Fluorescence diagnosis in gastrointestinal endoscopy. Endoscopy. 2000; 32 977-985
27 Uehlinger P, Zellweger M, Wagnieres G. et al . 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J Photochem Photobiol B. 2000; 54 72-80
28 Lange N, Jichlinski P, Zellweger M. et al . Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer. 1999; 80 185-193
29 Kiesslich R, Jung M. Magnification endoscopy: does it improve mucosal surface analysis for the diagnosis of gastrointestinal neoplasias?. Endoscopy. 2002; 34 819-822
30 Lambert R, Rey J F. Endoscopy and early neoplasia: better but not the best. Endoscopy. 2001; 33 348-352
31 Koop H. State-of-the-art review. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy. 2002; 34 97-103
32 Rösch T. DDW Report. Reflux disease and Barrett's esophagus. Endoscopy. 2002; 34 851-859
33 Ito S, Muguruma N, KusakaY . et al . Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro. Endoscopy. 2001; 33 849-853
34 DaCosta R S, Wilson B C, Marcon N E. New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. J Gastroenterol Hepatol. 2002; 17 S85-S104
35 Panjehpour M, Overholt B F, VoDinh T. et al . Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 1996; 111 93-101
36 Haringsma J, Tytgat G NJ, Yano H. et al . Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc. 2001; 53 642-650
37 Haringsma J, Prawirodirdjo W, Tytgat G NJ. Accuracy of fluorescence imaging of dysplasia in Barrett's esophagus. Gastroenterology. 1999; 116 G1832

C. Felley, M. D.

Centre Hospitalier Universitaire Vaudois (CHUV) · Division of Gastroenterology

1011 Lausanne · Switzerland

Fax: +41-21-3140707

Email: christian.felley@chuv.hospvd.ch